Latest Health Care News

Page 3 of 5
Ramsay Health Care has announced a fully franked ordinary dividend of AUD 0.40 per share for the six months ending June 2025, signaling steady returns for shareholders.
Ada Torres
Ada Torres
28 Aug 2025
Emyria Limited reports a reduced net loss of $3.14 million for FY2025, driven by strategic expansion in psychedelic-assisted mental health treatments and key partnerships including insurer Medibank. The company advances clinical services while continuing R&D on proprietary medicines.
Ada Torres
Ada Torres
28 Aug 2025
Ramsay Health Care reported a modest 1.7% increase in underlying net profit for FY25, driven by strong Australian and UK hospital performances despite significant impairments in the UK. The company is advancing its multi-year transformation and expects EBIT growth in Australia for FY26, though challenges remain.
Ada Torres
Ada Torres
28 Aug 2025
Ramsay Health Care posted solid revenue growth driven by its Australian and UK hospital businesses, despite a significant impairment charge impacting net profit. The group advances a multi-year transformation focusing on operational efficiency and capital discipline.
Ada Torres
Ada Torres
28 Aug 2025
Ramsay Health Care reported a 6.8% revenue increase and a modest rise in underlying profit for FY25, despite a significant impairment in its UK mental health division. The company maintains a strong dividend and outlines a cautiously optimistic outlook for FY26.
Ada Torres
Ada Torres
28 Aug 2025
RAM Essential Services Property Fund reported solid FY25 results, highlighting portfolio growth, strategic capital recycling, and a clear transition towards a pure healthcare real estate focus.
Eva Park
Eva Park
27 Aug 2025
RAM Essential Services Property Fund (REP) reported solid FY25 results, maintaining stable occupancy and delivering steady income while progressing its shift to a healthcare-focused REIT. The fund also announced a key board appointment as it looks ahead to further growth.
Eva Park
Eva Park
27 Aug 2025
Emyria has begun treating the first Medibank-funded PTSD patients at its Perth clinic, marking a pioneering step in private insurance coverage for psychedelic-assisted therapy in Australia. This milestone fuels rapid clinic expansion and supports the company’s national rollout strategy.
Ada Torres
Ada Torres
26 Aug 2025
Tryptamine Therapeutics has secured an exclusive agreement with leading neuroscientists to develop a novel EEG-based brain entropy biomarker aimed at enhancing precision psychiatry for its psychedelic drug TRP-8803.
Ada Torres
Ada Torres
21 Aug 2025
Neurizon Therapeutics reports encouraging topline results from its Phase 1 Open-Label Extension study of NUZ-001, demonstrating long-term safety and a significant survival advantage in ALS patients. These findings pave the way for the pivotal HEALEY ALS Platform Trial planned for late 2025.
Ada Torres
Ada Torres
20 Aug 2025
WAM Leaders Limited reported a strong $63.8 million net profit for FY2025 and declared a fully franked final dividend of 4.7 cents per share, despite its investment portfolio underperforming the benchmark index.
Claire Turing
Claire Turing
15 Aug 2025
Nutritional Growth Solutions has completed a $760,000 share placement at a slight discount, aiming to boost inventory and support its retail growth strategy.
Victor Sage
Victor Sage
5 Aug 2025